Industrial conglomerate 3M has committed $7.35 billion over a nine-year period to resolve a massive wave of litigation involving personal injury claims linked to per- and polyfluoroalkyl substances (PFAS), the man-made forever chemicals
used in products such as firefighting foam and stain-resistant clothing. The agreement is intended to address nearly 99% of existing personal injury claims, involving an estimated 115,000 to 120,000 eligible plaintiffs both inside and outside the Aqueous Film-Forming Foam Multi-District Litigation (AFFF MDL) currently in a federal court in South Carolina.
The company expects to record a pre-tax charge of approximately $5.8 billion in the fourth quarter of 2026, representing the discounted present value of the commitment. 3M stated that this charge will be treated as a special item in adjusted results and is not expected to impact its previously issued 2026 guidance. 3M noted that the charge would not change its forecast, citing the strength of its business model and free cash flow as sufficient to meet these obligations.
3M Staggers Payments over a Nine-Year Schedule
The nine-year payment schedule is designed to stagger cash flow against the company’s other obligations. According to the settlement terms, 3M will make a $50 million payment in 2026, followed by no payments in 2027. The final two years of the agreement will see approximately 20% of the total settlement paid out. The resolution includes a $680 million reserve fund that is part of the overall financial commitment to manage remaining and future claims.
To manage future litigation, the deal outlines several mechanisms:
- Payments contingent on plaintiffs choosing to join the resolution.
- A $680 million reserve for additional claims.
- An anticipated court order from the MDL establishing requirements for evidentiary and timing for plaintiffs who still intend to pursue litigation.
While the agreement provides a broad resolution, 3M did not admit liability and stated it remains prepared to continue defending itself in litigation if certain settlement conditions fail to materialize.
Context of PFAS Litigation and Manufacturing Changes
PFAS are manufactured chemicals that can build up in soil and water because they take a long time to disappear. These substances have been linked to various health issues, including kidney and testicular cancer, liver damage, reduced antibody response to vaccines, and lower birth weight. The settlement follows previous multi-billion dollar agreements, including a 2023 deal where 3M agreed to pay up to $12.5 billion over 13 years to help U.S. water suppliers address contamination.
This settlement is a significant milestone for 3M and substantially reduces litigation uncertainty,
said 3M Chairman and CEO William Brown.
In an effort to address the chemical’s impact, 3M has begun moving away from certain PFAS products and announced it has successfully completed a plan to discontinue the manufacture of all PFAS globally by the end of 2025. The company has also deployed advanced water treatment technology at sites where it previously produced the chemicals and will continue remediation efforts.
Following the announcement, 3M shares traded over 1% higher overnight, as the deal helped ease a major source of legal uncertainty for the company, which is currently on track for a third straight year of gains.